WeConnectPatients.com · Genetic & Liver Health

More than 90% of people with Alpha-1 don’t know they have it. One blood test could change that.

Alpha-1 antitrypsin deficiency is a genetic condition that can silently damage your liver for years before anyone catches it. Here’s what you need to know.

Undiagnosed

The vast majority of people with Alpha-1 don’t know they have it

Diagnostic Delay

Most people see multiple doctors before getting answers

Silent Fibrosis

Among those with the highest-risk genotype (PiZZ), more than a third have significant liver scarring without symptoms

Blood Test

A single blood test can start the diagnostic journey

Your body makes a protein that’s supposed to protect you. In Alpha-1, that protein turns against your liver.

Alpha-1 antitrypsin deficiency isn’t something you catch. It’s something you’re born with. A single gene mutation means your liver produces a misfolded version of a critical protein — and instead of going where it’s needed, that protein gets stuck, building up inside your liver cells.

Most people call it Alpha-1. Some just say “I’m an Alpha.” It’s one of the most common genetic conditions you’ve probably never heard of — affecting an estimated 70,000 to 100,000 people in the U.S. alone.

Here’s the part that’s hard to sit with: more than 90% of people who have it don’t know. The average person sees multiple doctors over 6 to 8 years before anyone orders the right test. Many get told it’s fatty liver disease, hepatitis, or something else entirely.

Alpha-1 is a dual-organ condition. The misfolded protein damages your liver from the inside. At the same time, your lungs lose the protection that protein was supposed to provide. Not everyone develops problems in both organs — but the risk is real for both.

The thing about Alpha-1 liver disease is that it can be completely silent. Among people with the highest-risk genotype (PiZZ), more than a third have significant liver scarring without feeling a thing. No pain. No symptoms. Just quiet damage happening beneath the surface.

What drives Alpha-1 liver disease

Alpha-1 is genetic. You either carry the mutation or you don’t. But several factors affect how the disease shows up.

A misfolded protein

Your liver produces a protein called alpha-1 antitrypsin (AAT). In Alpha-1, a gene mutation causes that protein to fold incorrectly. Instead of entering your bloodstream to protect your lungs, the misfolded protein clumps together inside liver cells — triggering inflammation and, over time, scarring.

Inherited from both parents

Alpha-1 follows an inheritance pattern called autosomal co-dominant — meaning both copies of the gene matter, one from each parent, and either can affect how the disease shows up. The highest-risk genotype (called PiZZ) means both copies carry the Z variant (mutation). If you have one Z copy and one normal copy (PiMZ), your risk is lower but not zero — especially if other liver stressors are present.

It runs in families

If one family member is diagnosed, close relatives should be tested. Siblings have a 1-in-4 chance of carrying the same genotype. Children of someone with PiZZ will carry at least one Z variant. Knowing your family’s status matters.

Cofactors that accelerate damage

Alcohol use, obesity, and viral hepatitis can speed up liver scarring in someone with Alpha-1. These aren’t the cause — the gene is — but they can speed up the damage your liver is already experiencing. Avoiding them gives your liver the best chance.

It affects all ethnicities

Alpha-1 has historically been called a “Northern European disease.” That framing has led to severe under-testing in Black, Hispanic, Asian, and Middle Eastern populations — despite documented cases across all groups. If you have unexplained liver disease, your ethnicity should never be a reason not to test.

Unpredictable progression

Two people with the exact same genotype can have very different outcomes. One person stays asymptomatic for life. Another develops cirrhosis (advanced liver scarring) by 50. Researchers don’t fully understand why yet — which makes regular monitoring essential.

How Alpha-1 is diagnosed

Diagnosing Alpha-1 starts with one simple blood test. The hard part is getting someone to order it.

AAT blood level

A serum alpha-1 antitrypsin level is the first step. It’s a routine blood draw — nothing specialized. If your level is low, it flags the need for genetic confirmation. This is the test that gets missed in over 90% of cases.

Genetic testing

A blood draw or cheek swab identifies your exact genotype — PiMM (normal), PiMZ (carrier), PiZZ (highest risk), or other variants. This tells you and your doctor exactly what you’re dealing with and what your family members should know.

Liver assessment

Once confirmed, your liver needs evaluation. Non-invasive tools like FibroScan (transient elastography) measure liver stiffness to estimate scarring. FibroScan availability varies by location — if it’s not available at your local facility, ask your hepatologist about alternative imaging options or a referral. Blood tests like FIB-4 (a scoring index calculated from routine bloodwork that helps estimate liver scarring) and liver function panels add to the picture. Some patients may need a liver biopsy for precise staging.

Ongoing monitoring

Alpha-1 liver disease requires regular surveillance — typically elastography and blood work every 6 to 12 months. If cirrhosis (advanced liver scarring) is present, ultrasound screening for liver cancer every 6 months is standard. Silent progression is the norm, not the exception.

Family screening

After your diagnosis, first-degree relatives — parents, siblings, children — should be tested. A genetic counselor can help you navigate those conversations and coordinate testing. Early identification can prevent years of diagnostic delay.

The honest picture on treatment

There is no approved disease-modifying treatment for Alpha-1 liver disease today. That’s the honest reality. But the landscape is changing fast — and there are still important things you and your doctor can do right now.

Current Standard

Monitoring & Lifestyle Management

Regular liver function tests, elastography, and imaging form the backbone of current care. Avoiding alcohol, managing weight, and staying physically active help protect your liver. It’s not a cure — but it’s not nothing. Proactive monitoring catches progression early, when options are broader.

Lung Protection

Augmentation Therapy

IV infusions of replacement AAT protein are FDA-approved for lung disease — but they don’t help the liver. Augmentation replaces what’s missing in your bloodstream to protect your lungs. The liver problem is different: it’s caused by protein stuck inside cells, not protein that’s absent.

Advanced Disease

Liver Transplant

For people with advanced cirrhosis, transplant is currently the only cure. The new liver produces normal protein, resolving both the liver accumulation and the systemic deficiency. Post-transplant outcomes for AATD liver disease are generally favorable — five-year survival rates reported in published literature are high, often exceeding 90% in experienced transplant centers. But organ availability is limited, and the journey to transplant is its own challenge.

Emerging Science

Investigational Therapies

New approaches are being studied that target the root cause — reducing or correcting the misfolded protein at the genetic level. Some are in advanced clinical trials. These therapies represent a fundamentally different approach to Alpha-1 liver disease. Clinical trials are how they become available.

All treatments carry potential side effects and eligibility requirements. Talk to your hepatologist about which options apply to your situation. If cost or insurance is a barrier to monitoring or care, ask your healthcare team about patient assistance options. Organizations like the Alpha-1 Foundation (alpha1.org) can also connect you with financial and support resources.

“For years, the only answer was ‘we’ll watch it.’ Now there are trials testing things that could actually change the course of this disease.”

Reflects common patient experiences

Some clinical trials provide monitoring and medications at no cost.

Answers to common questions

Living with Alpha-1 raises real, practical questions. Here are honest answers to some of the most common ones.

What does Alpha-1 fatigue actually feel like?

It’s not regular tired. People describe it as bone-deep exhaustion that sleep doesn’t fix. It can make you feel like you’re operating at 60% on a good day — affecting concentration and work, not just physical energy. If your fatigue is interfering with work or daily life, tell your hepatologist — it’s a real symptom, not something to push through. They can assess contributing factors and, where relevant, connect you with supportive resources.

Should I tell my family to get tested?

Yes. Alpha-1 is genetic, which means your siblings and children may carry the same gene. A simple blood test can tell them. It’s a hard conversation, but early detection can save someone years of misdiagnosis. A genetic counselor can help you figure out how to bring it up.

I feel fine. Do I really need all this monitoring?

You do. Among people with the highest-risk genotype (PiZZ), more than a third have significant liver scarring without any symptoms at all. Feeling fine doesn’t mean your liver is fine. Regular elastography and blood work are the only way to know what’s actually happening inside.

Does Alpha-1 affect mental health?

The weight of a genetic diagnosis, uncertainty about progression, guilt about passing it to children — including concerns about family planning and the future — all of it takes a toll. Depression and anxiety are more common in people with Alpha-1 than in the general population. If you’re struggling, that’s not weakness. Talk to your doctor about it. A genetic counselor can also be a valuable resource for navigating the hereditary and reproductive dimensions of Alpha-1 specifically.

I was told this is a “white disease.” Is that true?

No. Alpha-1 is most common in people of Northern European descent, but it exists across all races and ethnicities. The problem is that non-white populations are dramatically under-tested — only about 5% of eligible patients get screened. If you have unexplained liver disease, you deserve testing regardless of your background.

What’s the difference between the liver and lung sides of Alpha-1?

Same gene, different mechanisms. In your lungs, the missing protein leaves tissue unprotected from damage — that’s what causes emphysema. In your liver, the misfolded protein accumulates inside cells and causes inflammation and scarring. Augmentation therapy helps the lungs but doesn’t address the liver. They’re two separate problems from one genetic cause.

Can I drink alcohol?

The strong recommendation is to avoid it entirely, or limit it as much as possible. Alcohol is a direct liver toxin, and when your liver is already under stress from Alpha-1, even moderate drinking can accelerate scarring. This isn’t a moral judgment — it’s biology.

Are there others like me?

Absolutely. The Alpha-1 community is close, active, and well-connected. The Alpha-1 Foundation connects patients, funds research, and runs clinical resource centers. Online groups, peer support networks, and local meetups exist. Many people say finding their community made a significant difference in how they managed their diagnosis. You don’t have to figure this out alone.

Research & Progress

The science is at a turning point

The science of Alpha-1 liver disease is at a turning point. For decades, the only options were monitoring and waiting — or transplant. Now, researchers are testing therapies that go after the root cause: the misfolded protein itself. Some approaches aim to reduce how much of it your liver makes. Others are working to correct the gene directly.

As of early 2026, multiple clinical trials are actively enrolling, including some advanced-stage studies. The research landscape for Alpha-1 liver disease has advanced significantly in recent years. Early research has shown changes in disease-related biomarkers that have encouraged continued investigation. Longer-term outcomes are still being established through ongoing trials.

Clinical trials are how these treatments get tested and eventually reach patients. Participating means access to specialized care teams, close monitoring, and emerging therapies — while contributing to research that could change the future for everyone with Alpha-1. There’s no obligation. Your standard care continues either way. It’s your decision.

You’ve been waiting long enough for answers. Now there may be real options.

Clinical research for Alpha-1 liver disease is advancing faster than ever. Whether you were just diagnosed or have been living with this for years, there may be studies worth exploring.

Not sure where to start?

Walking into a hepatology appointment with the right questions changes everything. We put together a quick guide.

This content is for educational purposes only and isn’t a substitute for medical advice. Talk to your healthcare provider before making decisions about your care. Information about clinical trials is for general awareness, not an endorsement of any specific study.

Sources: Alpha-1 Foundation, ATS/ERS, AASLD, EASL, NIH/NCBI, Mayo Clinic, Hepatology Communications, Gastroenterology, Journal of Hepatology, Nature Reviews Disease Primers, peer-reviewed literature (2003–2025), ClinicalTrials.gov.

WeConnect is a Takeda initiative connecting people to clinical trial opportunities. Visit WeConnectPatients.com.